Evidence map›Paper›PMID 41596744›Full record

ArticleInternational journal of molecular sciences2026

Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO).

Marta Pirola, Eleonora Molinaro, Samantha Manfredini, Riccardo Cuoghi Costantini, Chiara Carlucci, Claudia Piombino, Stefania Pipitone, Maria Giuseppa Vitale, Roberto Sabbatini, Francesca Bacchelli and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marta PirolaDivision of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Eleonora MolinaroOncology Area Sud AUSL Modena, Ospedale of Sassuolo, 41049 Sassuolo, Italy.ORCID 0000-0002-2068-0299
Samantha ManfrediniDivision of Molecular Pathology and Predictive Medicine, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.
Riccardo Cuoghi CostantiniStatistics Unit, Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Chiara CarlucciDivision of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Claudia PiombinoDivision of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.ORCID 0000-0002-7224-4536
Stefania PipitoneDivision of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.
Maria Giuseppa VitaleDivision of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.
Roberto SabbatiniDivision of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.
Francesca BacchelliClinical Trials Office, Division of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Laura BotticelliDepartment of Pathology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.
Albino EccherDepartment of Pathology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.
Roberto D'AmicoStatistics Unit, Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Lucia LongoOncology Area Sud AUSL Modena, Ospedale of Sassuolo, 41049 Sassuolo, Italy.
Stefania BettelliDivision of Molecular Pathology and Predictive Medicine, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.
Cinzia BaldessariDivision of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy.ORCID 0000-0003-3051-8057
Massimo DominiciDivision of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy.

Funding

Azienda Ospedaliero-Universitaria of Modena PRGT No. 419
6 · The paper itself

Abstract

Despite the introduction of novel therapeutic options, the prognosis of advanced endometrial cancer remains poor. In recent years, increasing attention has been directed toward the molecular characterization of endometrial cancer. However, data specifically focusing on advanced-stage disease are still limited. In our single-center, retrospective, exploratory study with a limited sample size, we analyzed 32 patients with advanced or recurrent endometrial cancer treated at the Modena Cancer Center. Comprehensive molecular profiling was performed to assess DNA mutations, copy number variations, and RNA expression. We characterized the molecular landscape of this cohort, evaluated selected genomic alterations across predefined clinical subgroups, and explored their association with overall survival. Consistent with previous reports, a high prevalence of

Indexed as

Endometrial NeoplasmsAgedbeta CateninBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesDNA Copy Number VariationsFemaleHumansMutationPrognosisProtein Phosphatase 2Proto-Oncogene Proteins p21(ras)PTEN PhosphohydrolaseRetrospective StudiesTumor Suppressor Protein p53beta CateninBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesCTNNB1 protein, humanKRAS protein, humanPIK3CA protein, humanPPP2R1A protein, humanProtein Phosphatase 2Proto-Oncogene Proteins p21(ras)PTEN PhosphohydrolasePTEN protein, humanTP53 protein, humanTumor Suppressor Protein p53endometrial cancermolecular analysisprognosis and treatments

Identifiers

PMID41596744
PMCPMC12842487

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.